Efficacy and safety of hyperbaric oxygen therapy for fibromyalgia: a systematic review and meta-analysis
Authors:
Open Access
Abstract
Objective: To investigate the efficacy and safety of hyperbaric oxygen therapy (HBOT) for fibromyalgia (FM). Design: A systematic review and meta-analysis. Data sources: PubMed, EMBASE, Cochrane Library, Web of Science, VIP (China Science and Technology Journal Database), CNKI (China National Knowledge Infrastructure) and WanFang database were searched from from inception to 22 October 2022. Eligibility criteria: We included clinical trials (randomised controlled and non-randomised controlled trials) of HBOT for FM. Data extraction and synthesis: Two researchers independently screened the literature, extracted data and evaluated the quality of the included studies, with disagreements resolved by a third researcher. The Cochrane Collaboration checklists and the Methodological Index for Non-randomised Studies were used to assess the risk of bias. Meta-analysis was performed by RevMan V.5.4.1 software. Random effect models were used for meta-analysis. Results: Nine studies were included in this review, with a total of 288 patients. For pain assessment, we combined the results of the Visual Analogue Scale and Widespread Pain Index. The results showed that HBOT could relieve the pain of FM patients compared with the control intervention (standardised mean difference=−1.56, 95% CI (−2.18 to –0.93), p I 2 =51%). Most included studies reported that HBOT ameliorated tender points, fatigue, multidimensional function, patient global and sleep disturbance in FM. Adverse events occurred in 44 of 185 patients (23.8%). Twelve patients (6.5%) withdrew because of adverse reactions. No serious adverse events or complications were observed. Conclusions: HBOT might have a positive effect in improving pain, tender points, fatigue, multidimensional function, patient global and sleep disturbance in FM, with reversible side effects. Low pressure (less than 2.0 atmospheric absolute) may be beneficial to reduce adverse events in FM. Further studies should be carried out to evaluate the optimal protocol of HBOT in FM. PROSPERO registration number: CRD42021282920.Keywords
Funding Information
- 1·3·5 project for disciplines of excellence–Clinical Research Incubation Project, West China Hospital, Sichuan University (No. 2021HXFH063)
- Key research and development project of Sichuan Provincial Science and Technology Department (No. 2018SZ0082)
This publication has 64 references indexed in Scilit:
- Hyperbaric Oxygen Therapy Can Improve Post Concussion Syndrome Years after Mild Traumatic Brain Injury - Randomized Prospective TrialPLOS ONE, 2013
- Hyperbaric Oxygen Induces Late Neuroplasticity in Post Stroke Patients - Randomized, Prospective TrialPLOS ONE, 2013
- Attenuating inflammation but stimulating both angiogenesis and neurogenesis using hyperbaric oxygen in rats with traumatic brain injury2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Chronic widespread pain: From peripheral to central evolutionBest Practice & Research Clinical Rheumatology, 2011
- Interpretation of random effects meta-analysesBMJ, 2011
- Hyperbaric Oxygen Treatment Induces a 2-Phase Antinociceptive Response of Unusually Long Duration in MiceThe Journal of Pain, 2010
- Fibromyalgia Syndrome Module at OMERACT 9: Domain ConstructThe Journal of Rheumatology, 2009
- Potential Benefits of Non-Pharmacological Therapies in FibromyalgiaThe Open Rheumatology Journal, 2008
- Hyperbaric Oxygen as an Adjuvant for AthletesSports Medicine, 2005